Is Pain Sensitivity Genetic? What COMT, OPRM1, and CYP2D6 Mean for Your Pain

You wake up after surgery and the nurse asks you to rate your pain on a scale of one to ten. You say eight. The patient in the next bed — same procedure, same surgeon, same anesthesia protocol — says four. You end up needing twice the morphine before the pain becomes manageable. Nobody questions whether the other patient is tougher than you. But nobody explains why you needed more, either.

Or maybe it is something smaller. Your friend takes ibuprofen for a headache and feels relief within twenty minutes. You take the same dose and barely notice a difference an hour later. You have always chalked it up to randomness, or assumed you were not taking enough. But the pattern keeps repeating.

These are not flukes. Research over the past two decades has identified specific genetic variants that directly influence how intensely you perceive pain and how effectively pain medications work in your body. The science is not speculative — it is published in journals like Science, Anesthesiology, and Pain, and the clinical implications are significant enough that some hospitals now incorporate genetic testing into pre-surgical planning.

The Genetics of Pain Perception

Pain perception is not a single dial that gets turned up or down. It involves neurotransmitter clearance, receptor binding, emotional processing, and inflammatory signaling — and each of these pathways has genetic variation. Two genes stand out for having the strongest and most replicated evidence.

COMT Val158Met: The Warrior/Worrier Variant

The COMT gene encodes catechol-O-methyltransferase, an enzyme that breaks down dopamine, norepinephrine, and epinephrine in your brain. A single-letter change at position 158 — valine (Val) to methionine (Met) — reduces the enzyme's activity by up to four-fold. This variant is sometimes called the "warrior/worrier" polymorphism because of its effects on stress response and pain processing.

Val/Val (warrior) — high COMT activity. These individuals clear pain-related neurotransmitters quickly. They tend to have higher pain thresholds and better stress tolerance under acute pressure. In experimental settings, Val/Val subjects consistently report lower pain scores.

Met/Met (worrier) — low COMT activity. Neurotransmitters like dopamine linger longer in synapses. This is associated with increased pain sensitivity, higher anxiety under stress, and greater opioid requirements after surgery. A landmark 2003 study by Zubieta et al. in Science showed that Met/Met individuals had measurably reduced mu-opioid system activation during sustained pain — meaning their brains were less effective at mounting a natural pain-dampening response.

Val/Met (intermediate) — moderate COMT activity. Pain sensitivity falls between the two extremes. This is the most common genotype.

The practical implication: if you carry Met/Met, you may genuinely experience more pain from the same stimulus than someone with Val/Val. This is a biological difference, not a psychological one.

OPRM1 A118G: The Opioid Receptor Variant

The OPRM1 gene encodes the mu-opioid receptor — the primary target that morphine, fentanyl, hydrocodone, and your body's own endorphins bind to in order to reduce pain. The A118G variant (rs1799971) swaps adenine for guanine at position 118, which reduces receptor expression on cell surfaces and alters binding affinity.

The clinical consequence is well-documented. A meta-analysis published in Anesthesiology found that patients carrying the G allele required 30–50% more morphine to achieve the same level of post-operative pain relief as patients with the A/A genotype. This is not about tolerance — these patients had never taken opioids before. Their receptors simply bind opioid molecules less effectively.

About 10–15% of people of European descent and up to 40% of people of East Asian descent carry at least one copy of the G allele. If you have ever felt like opioid pain medications "don't work as well" for you as they seem to for others, this variant may be part of the explanation.

How Pain Genetics Affect Medication Response

Beyond pain perception itself, your genetics also determine whether specific pain medications can even be activated in your body. This is where pharmacogenomics — the study of how genes affect drug response — becomes directly relevant.

CYP2D6 and Opioid Metabolism

Several commonly prescribed opioids are prodrugs. They are pharmacologically inactive in the form you swallow — your liver must convert them into the active compound that actually relieves pain. The enzyme responsible for this conversion is CYP2D6.

Codeine must be converted to morphine by CYP2D6. If you are a CYP2D6 poor metabolizer, you produce little or no functional enzyme. Codeine will not work for you, regardless of dose. At the other extreme, ultrarapid metabolizers convert codeine to morphine too quickly, creating dangerously high morphine levels — a risk serious enough that the FDA issued a boxed warning.

Tramadol follows the same pattern. CYP2D6 converts tramadol to its active metabolite O-desmethyltramadol. Poor metabolizers get minimal analgesic effect. Ultrarapid metabolizers face toxicity risk.

Hydrocodone is partially activated by CYP2D6 into hydromorphone. While hydrocodone has some inherent activity on its own, CYP2D6 poor metabolizers may experience reduced efficacy compared to normal metabolizers.

About 6–10% of people of European descent are CYP2D6 poor metabolizers. Another 1–2% are ultrarapid metabolizers. Neither group will respond to codeine or tramadol in the expected way, and neither group will know this without genetic testing.

Beyond Opioids: CYP2C9 and NSAIDs

CYP2C9 metabolizes several non-steroidal anti-inflammatory drugs, including celecoxib (Celebrex) and ibuprofen. CYP2C9 poor metabolizers clear these drugs more slowly, leading to higher blood levels and increased risk of gastrointestinal bleeding and cardiovascular side effects. This matters for pain management because NSAIDs are often the first-line treatment.

What Your DNA Can and Cannot Tell You

Genetic testing for pain sensitivity is genuinely useful, but it has boundaries. Here is an honest assessment of what it does and does not do.

What genetic testing can tell you:

• Your COMT Val158Met genotype and what it means for baseline pain sensitivity
• Your OPRM1 A118G status and whether you may need adjusted opioid dosing
• Your CYP2D6 metabolizer phenotype and whether codeine, tramadol, and similar prodrugs will actually work in your body
• Your CYP2C9 status and implications for NSAID safety

What genetic testing cannot tell you:

• Your exact pain score for a specific injury or procedure — pain is influenced by inflammation, psychological state, sleep, prior experiences, and dozens of other non-genetic factors
• Whether chronic pain conditions like fibromyalgia or neuropathy are present — these involve complex mechanisms beyond single gene variants
• How you will respond to every pain medication — genetic testing covers the drugs with strong pharmacogenomic evidence, not all analgesics

The value of genetic testing is not in predicting your pain with precision. It is in identifying the biological variables that are known, measurable, and actionable — so your doctor can make better-informed decisions about which medications to prescribe and at what dose.

What to Do With This Information

If you suspect your pain sensitivity or medication response has a genetic component, here are concrete steps you can take.

Before surgery: Share your pharmacogenomic results with your anesthesiologist and surgeon during the pre-op consultation. If you carry OPRM1 A118G, they may adjust your opioid dosing protocol. If you are a CYP2D6 poor metabolizer, they will know to avoid codeine and tramadol entirely. Read more about pharmacogenomics before surgery.

Before starting opioid prescriptions: Request a pharmacogenomic review. If your doctor is prescribing codeine or tramadol without knowing your CYP2D6 status, the prescription may be ineffective or dangerous. A one-time genetic test eliminates this uncertainty for every future prescription.

For chronic pain management: If you have been cycling through pain medications without finding one that works well, genetic testing can identify whether the problem is metabolic (your body is not activating the drug) rather than pharmacological (the drug is wrong for your condition).

Talk to your doctor: Bring a clinician-ready summary to your appointment. DecodeMyBio's reports include a one-page clinician summary specifically designed for this — your doctor can review your metabolizer phenotypes and receptor variants in under a minute.